You are here: Home » Companies » News
FIFA video game to disappear as EA Sports decades-long partnership ends
End of an era: Apple drops last iPod model after two decades
Business Standard

Cipla will use Covid-19 bulk drugs inventory when demand rises

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said

Topics
Cipla | Cipla Roche | Cipla results

Sohini Das 



Cipla, Cipla logo, Cipla headquarters
Photo: Reuters

Mumbai-based Cipla, which reported a one-time cost of Rs 200 crore for Covid-19 inventory and other charges in the March quarter (Q4), is sitting on inventory of the antibody cocktail drug from Roche, some bulk drug of remdesivir, and some stocks of molnupiravir. The Covid-19 portfolio contributed 5-6 per cent of Cipla’s turnover during peak Covid waves, the firm said.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Wed, May 11 2022. 23:46 IST

RECOMMENDED FOR YOU

.